Jeff Friedman
Managing Partner, Friedman Bioventure
Jeff Friedman is listed as Managing Partner, Friedman Bioventure. Jeff is scheduled to speak at Advanced Therapies Week 2027 on 18 January 2027.
Compiled from published conference agendas; not yet confirmed by Jeff. Is this you? Claim this profile.
About
Dr. Friedman oversees a family office that focuses on private companies in the biotechnology and pharmaceutical space, with an emphasis on platform technologies, oncology, neurodegenerative disease and genomics. For several years he ran the life science screening process for NuFund (formerly Tech Coast Angels, San Diego), the largest angel investing group in the US. He currently serves on the boards of Hillhurst Bio and Trio Pharma and as observer for Conarium Bioworks, Saccharo and Switchback Therapeutics. He was a board member, served as COO and was a scientific advisor at DTx Pharma from the initial financing up to the acquisition by Novartis in 2023. Dr. Friedman is trained as a Pediatrician and Hematologist/Oncologist.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Ask the Investors: Your questions, Their answers Speaker · 18 January 2027
- Investment Summit Speaker · 18 January 2027
Spoke alongside
People who have shared a session with Jeff at events on B2DB.
- Sven Kili Partner · Saisei Ventures 2 shared sessions
- Alan Moazzam Health Sciences Associate Clinical Professor · UC San Diego Health 1 shared session
- Jack Florio Managing Director · IPL Capital Advisory 1 shared session
- James Zanewicz CEO · CONNECT 1 shared session
- Misti Cain Executive Producer & Host · The Pitch 1 shared session
- Randy Berholtz Senior Advisor · Mesa Verde Venture Partners 1 shared session
- Yisrael Katz Founder · Blue Marble Network 1 shared session